Vioxx Research Today is a free monthly online journal that collates and summarizes the latest research about Vioxx, including details on osteoarthritis, side-effects, trials, stroke, heart attack.

Volume 2 (2005), Issue 10 (October)

1. Cardiovascular safety of lumiracoxib: A meta-analysis of all randomized controlled trials >/=1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
   Clin Ther, 27(8): 1196-214. [Abstract] [Full-text]
2. Importance of the pineal gland, endogenous prostaglandins and sensory nerves in the gastroprotective actions of central and peripheral melatonin against stress-induced damage.
   J Pineal Res, 39(4): 375-85. [Abstract] [Full-text]
3. Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism.
   J Clin Endocrinol Metab, 90(10): 5754-60. [Abstract] [Full-text]
4. Comparison of conventional NSAIDs and cyclooxygenase-2 inhibitors in outpatients.
   Joint Bone Spine, 72(5): 397-402. [Abstract] [Full-text]
5. Aromatase inhibitors and cyclooxygenase-2 (COX-2) inhibitors in endometriosis: new questions--old answers?
   Eur J Obstet Gynecol Reprod Biol, 122(2): 144-50. [Abstract] [Full-text]
6. Pharmacological investigation of trimetazidine in models of inflammation, pain and gastric injury in rodents.
   Pharmacology, 75(3): 122-32. [Abstract] [Full-text]
7. Essay: the political logic of regulatory error.
   Nat Rev Drug Discov, 4(10): 819-23. [Abstract] [Full-text]
8. Biphasic effect of prostaglandin E2 in a rat model of esophagitis mediated by EP1 receptors: relation to pepsin secretion.
   Digestion, 72(2): 109-18. [Abstract] [Full-text]
9. Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer.
   Oncologist, 10(9): 710-7. [Abstract] [Full-text]
10. Preoperative use of selective COX-II inhibitors for pain management in laparoscopic nissen fundoplication.
    Surg Endosc, 19(9): 1182-7. [Abstract] [Full-text]
11. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?
    Drug Metab Dispos, 33(11): 1567-75. [Abstract] [Full-text]
12. Design, synthesis, and biological evaluation of linear 1-(4-, 3- or 2-methylsulfonylphenyl)-2-phenylacetylenes: a novel class of cyclooxygenase-2 inhibitors.
    Bioorg Med Chem, 13(23): 6425-34. [Abstract] [Full-text]
13. Celecoxib and cardiovascular risks.
    Expert Opin Drug Saf, 4(6): 1005-15. [Abstract] [Full-text]

© 2004-2008 Vioxx Research Today. All Rights Reserved.